Immunometabolism therapies could offer a way to reverse inflammation and cure diseases, according to Neil Weir, CEO of Sitryx. This emerging field in therapeutics looks at the overlap between metabolic pathways and the immune cell synthesis process, allowing very specific targeted therapies which influence the immune system without causing dangerous side effects. Sitryx has three drugs in various stages of development for a variety of autoimmune diseases, while Texas-based ImmunoMet is likewise developing lixumistat, which has various uses including in pancreatic cancer trials.
Apple 0-Day Vulnerabilities Exploited in Sophisticated Attacks Targeting iPhone Users
Apple patches two WebKit zero-day flaws actively exploited in sophisticated attacks targeting specific iPhone users running iOS versions prior to 26. The iOS 26.2 and
